Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 6 publications
A phase II trial of UGT1A1 genotype-guided FOLFIRI plus bevacizumab as first-line therapy for advanced, unresectable colorectal cancer.
Journal: The oncologist
Published: February 20, 2024
Phase I/II trial of nano-camptothecin CRLX101 with capecitabine and radiotherapy as neoadjuvant treatment for locally advanced rectal cancer.
Journal: Nanomedicine : nanotechnology, biology, and medicine
Published: November 03, 2018
A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: March 06, 2016
A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: October 23, 2015
A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: January 25, 2015
Showing 1-6 of 6
Last Updated: 09/26/2026